VaxForm specializes in the development of vaccine formulations. Press Releases: 01Sep2020 - VaxForm was awarded a NSF SBIR Phase I grant to develop a COVID-19 vaccine using their oral delivery platform. 11Oct2016 - VaxForm has published the results of their non-clinical safety evaluation of their vaccine targeting S.pyogenes in the Journal of Applied Toxicology. The article citation is: Preclinical safety study of a recombinant Streptococcus pyogenes vaccine formulated with aluminum adjuvant. Harm HogenEscha, Anisa Dunham, Elodie Burlet, Fangjia Lu, Yung-Yi C. Mosley and Garry Morefield. J Applied Toxicology 2016 01Jul2014 - VaxForm has published the results of their pre-clinical development studies for their vaccine targeting S.pyogenes in the journal Vaccine. The article demonstrates the potency and stability optimization that has been achieved during formulations development. The article citation is: Development of a recombinant fusion protein vaccine formulation to protect against Streptococcus pyogenes, Vaccine 32 (2014), pp. 3810-3815. 28May2014 - VaxForm & EMD Millipore present a poster entitled "Tangential Flow Filtration Application for the Purification and Production of S. pyogenes vaccine from E. Coli inclusion bodies" at the 2014 AAPS National Biotechnology Conference in San Diego, CA. In this work, Vaxform LLC and EMD Millipore have collaborated to develop membrane-based unit operations for the purification of inclusion bodies from a bacterial expression system. The product being purified was a recombinant fusion protein antigen targeting S. pyogenes.
View Top Employees from VaxFormWebsite | http://www.vaxform.com |
Revenue | $202000 |
Employees | 6 (5 on RocketReach) |
Founded | 2010 |
Address | 116 Research Drive, Bethlehem, Pennsylvania 18015, US |
Phone | (610) 573-9620 |
Technologies |
HTML,
Twitter,
Polyfill
+5 more
(view full list)
|
Industry | Biotechnology Research, Chemicals, Petrochemicals, Glass & Gases, Pharmaceuticals, Manufacturing, Other Healthcare Services |
Web Rank | 25 Million |
Competitors | Bon Opus Biosciences, Proteos, exonbio |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 325414 Companies |
Looking for a particular VaxForm employee's phone or email?
The VaxForm annual revenue was $202000 in 2024.
Garry Morefield is the President of VaxForm.
5 people are employed at VaxForm.
VaxForm is based in Bethlehem, Pennsylvania.
The NAICS codes for VaxForm are [3254, 325, 32541, 32, 325414].
The SIC codes for VaxForm are [283, 28].